Your DNA May Reveal Better Medication Options, Study Finds

Date:

Your DNA might hold critical insights that your physician overlooks when recommending medications.

According to a study released on Wednesday in Science Translational Medicine, approximately 25% of participants were given medications that could have necessitated an alternative drug or a different dosage based on their genetic information.

Conducted by researchers from the University of Pittsburgh, the study focused on 16 genes that influence the body’s reaction to medications.

The DNA samples of 98,590 individuals enrolled in the National Institutes of Health’s All of Us Research Program were evaluated and correlated with their medical histories where available.

Each participant possessed at least one significant genetic variation impacting their response to specific medications, with the average individual carrying nine variations. Among those with both genetic and clinical data, 24.4% had been prescribed at least one medication that, according to genetic guidelines, should have been substituted with another or adjusted in dosage.

Nonetheless, the research did not establish whether patients faced side effects or if their medications were less effective due to genetic factors.

Dr. Philip Empey, the study’s senior author and an associate professor at the University of Pittsburgh School of Pharmacy, asserts that understanding a patient’s genetic composition could minimize the trial-and-error approach in medicine.

“Anything we can do to more accurately predict the optimal medications and the appropriate dosages upfront can significantly reduce trial and error,” he stated.

A woman in a medical mask sorts pills on a counter.

A pharmacist organizes medications at a pharmacy in Vancouver in October 2022. Genetic differences can influence how patients respond to certain medications, potentially necessitating adjustments in dose or alternative prescriptions. (Darryl Dyck/The Canadian Press)

Identifying the Appropriate Medication

Some of the most frequently prescribed medications for participants with genetic profiles suggesting treatment modifications included omeprazole and pantoprazole for acid reflux, as well as atorvastatin for cholesterol management.

Empey mentions that certain genetic variations can heighten the risk of muscular issues when patients take statins like atorvastatin, which are intended to lower the risk of heart attacks or strokes.

This information could enable physicians to opt for alternative medications or adjust existing therapies.

“It empowers clinicians to make more informed decisions, such as considering different cholesterol medications, starting at a lower dose, setting a maximum limit, or closely monitoring for specific side effects,” Empey explained.

In some cases, the implications can be even more critical.

For instance, experts consulted by CBC News indicate that genetic testing can help pinpoint patients who are unlikely to have a positive response to clopidogrel (Plavix), a medication used to prevent blood clots after cardiac stenting, allowing for alternative treatments.

A man in a suit and tie sits in a laboratory.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health. He emphasizes that while genetic testing can guide medication choices, other factors such as diet, lifestyle, and existing medications must also be considered. (CBC)

A Blueprint, Not a Guarantee

Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), noted that the findings were not unexpected, although he was particularly struck by the genetic diversity and representation of individuals of African descent.

Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had already experimented with two or three antidepressants without success.

He points out that about 8 to 10% of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, causing the drugs to accumulate and potentially leading to side effects.

Kennedy believes genetic testing is particularly advantageous for patients who have faced difficulties with multiple medications.

However, he warns that DNA testing alone cannot predict a patient’s response to a specific medication. Factors such as other medications, smoking habits, and diet must also be factored in.

“We say, ‘Here’s your genetic blueprint, here are some tendencies you may have, and now let’s discuss all other considerations before making a final decision,'” he noted.

A 2023 European clinical trial referenced in the study indicated that performing genetic tests prior to prescribing certain medications led to a reduction in adverse drug reactions. However, integrating such testing into routine practice in Canada poses significant challenges.

A person in purple gloves points to a small plastic test tube.

A researcher at the University of Calgary holds a diagnostic kit used to identify genetic variations in February 2024. Although such testing could assist doctors in customizing medications for individual patients, its widespread implementation in Canada faces financial and practical obstacles. (Jeff McIntosh/The Canadian Press)

Challenges of Widespread Testing in Canada

Dr. Jacob Udell, a cardiologist in Toronto, expressed admiration for the study, particularly for the genetic diversity of its participants. However, he noted that few healthcare providers in Canada or the U.S. routinely check for genetic variations to understand how patients metabolize medications.

“It’s not typically on the radar of front-line clinicians,” he remarked.

Udell explained that for many ailments, physicians can prescribe medications, observe the patient’s reaction, and make necessary adjustments, often without severe consequences. This method can be more feasible than routinely screening for genetic differences.

He also questioned whether widespread genetic testing should take precedence when Canada’s healthcare system is already struggling to deliver fundamental services.

“We’re just trying to ensure everyone has access to a family doctor,” he added.

In addition to the costs associated with genetic testing, Udell emphasized that healthcare providers would need access to test results and the expertise to interpret them.

Empey concurred that making genetic testing standard practice would necessitate a significant investment in training, infrastructure, and new systems for sharing results among healthcare professionals.

“The science supporting many medications is robust. The challenge of implementation is more economic, process-oriented, and educational,” he concluded.

For the time being, Empey recommends that patients inquire with their doctors or pharmacists about the potential benefits of genetic testing and share any relevant results with them.

Udell cautioned that private genetic testing could become more prevalent among those who can afford it, “but that won’t assist those who cannot bear the costs.”

Source

Share post:

spot_imgspot_img

Popular

More like this
Related

Dabrowski and Stefani Power to U.S. Open Doubles Quarterfinals

Gabriela Dabrowski from Canada and her Brazilian partner Luisa...

Patrick Clancy Fights Back Against Online Misinformation Campaign

WARNING: This article includes information about violence towards...

Edmonton Pride Festival Faces Bomb Threat Amid Controversial Police Presence

An organizer of the Edmonton Pride Festival has disclosed...

10% of Federal Workers Face Office Return Delays Amid Space Issues

According to Public Services and Procurement Canada (PSPC), around...